| 2.96 0.13 (4.59%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.48 | 1-year : | 3.34 |
| Resists | First : | 2.13 | Second : | 2.85 |
| Pivot price | 1.6  |
|||
| Supports | First : | 0.94 | Second : | 0.79 |
| MAs | MA(5) : | 1.07 |
MA(20) : | 1.78 |
| MA(100) : | 3.65 |
MA(250) : | 5.78 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 5.1 |
| RSI | RSI(14): 22.8 |
|||
| 52-week | High : | 30.39 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FWBI ] has closed above bottom band by 19.3%. Bollinger Bands are 7.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 0.97 - 0.97 | 0.97 - 0.98 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Thu, 16 May 2024
First Wave BioPharma Changes Name to Entero Therapeutics - Yahoo Finance
Fri, 10 May 2024
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market - GlobeNewswire
Thu, 09 May 2024
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month - GlobeNewswire
Wed, 27 Mar 2024
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Thu, 14 Mar 2024
Why Is First Wave BioPharma (FWBI) Stock Up Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 47 (K) |
| Shares Short P.Month | 55 (K) |
| EPS | -47.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.1 % |
| Return on Equity (ttm) | -15.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|